Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

F0005000

Famotidin

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

Famotidin, N′-(Aminosulfonyl)-3-{[2-(diaminomethylenamino)-4-thiazolyl]-methylthio}-propanamidin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C8H15N7O2S3
CAS-Nummer:
76824-35-6
Molekulargewicht:
337.45
MDL-Nummer:
MFCD00079297
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329799617
NACRES:
NA.24

Biologische Quelle

synthetic

Qualität

pharmaceutical primary standard

Agentur

EP Reference Standard

API-Familie

famotidine

Form

solid

Verpackung

pkg of 110 mg

Hersteller/Markenname

EDQM

Lagerbedingungen

protect from light

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Versandbedingung

ambient

Lagertemp.

2-8°C

SMILES String

N\C(N)=N\c1nc(CSCCC(=N)NS(N)(=O)=O)cs1

InChI

1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

InChIKey

XUFQPHANEAPEMJ-UHFFFAOYSA-N

Angaben zum Gen

human ... HRH2(3274)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

Famotidine is a hydrophilic, cationic, histamine H2 receptor antagonist drug that effectively inhibits gastric acid secretion in humans.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

H2 Histamin-Rezeptorantagonist; Antiulcusmittel

Verpackung

Dieses Produkt wird, wie von der entsprechenden Pharmakopöe geliefert, angeboten. Die aktuellen Mengeneinheiten finden Sie im Referenzsubstanzen-Katalog der EDQM.

Sonstige Hinweise

Sales restrictions may apply.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

H Echizen et al.
Clinical pharmacokinetics, 21(3), 178-194 (1991-09-01)
Famotidine is a potent histamine H2-receptor antagonist widely used in the treatment and prevention of peptic ulcer disease. After intravenous administration the plasma famotidine concentration-time profile exhibits a biexponential decay, with a distribution half-life of about 0.18 to 0.5h and
M C Martinez
The Annals of pharmacotherapy, 33(6), 742-747 (1999-07-20)
To evaluate the use and potential benefit of famotidine in the management of schizophrenia. Clinical literature accessed through MEDLINE (February 1998-October 1998). Key search terms included famotidine, schizophrenia, and histamine. Schizophrenia is a complicated disorder associated with high morbidity if
A N Chremos
Journal of clinical gastroenterology, 9 Suppl 2, 7-12 (1987-01-01)
Famotidine is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect in humans is inhibition of gastric acid secretion. Dose-related suppression of basal and stimulated (meal, pentagastrin) gastric acid output has been shown with oral doses of 5-40 mg. The
C W Howden et al.
Clinical therapeutics, 18(1), 36-54 (1996-01-01)
Famotidine is a specific, long-acting histamine2-receptor antagonist. It is indicated for the treatment of duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Since its introduction for the treatment of acid-related disorders in 1985, an estimated 18.8 million patients
[Famotidine--a new histamine H2 receptor blockader].
P Ia Grigor'ev et al.
Klinicheskaia meditsina, 69(4), 23-28 (1991-04-01)
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.